Form 4: Nuvalent CSO Henry Pelish Reports Routine Stock Transactions Under Pre-Planned Programs

Nuvalent, Inc.'s Chief Scientific Officer, Henry E. Pelish, reported a series of pre-planned stock sales and option exercises totaling a net decrease of 2,145 shares in his direct beneficial ownership of Class A Common Stock.

Summary

• Henry E. Pelish, Chief Scientific Officer of Nuvalent, Inc. (NUVL), engaged in multiple transactions involving the company's Class A Common Stock on July 9 and July 10, 2025.
• On July 9, 2025, Pelish sold a total of 2,145 shares (1,945 shares at a weighted average price of $81.08 and 200 shares at a weighted average price of $81.90) to satisfy tax withholding obligations upon the vesting of previously granted equity awards, pursuant to a Rule 10b5-1 sell-to-cover instruction letter dated December 6, 2023.
• On July 10, 2025, Pelish exercised stock options to acquire a total of 5,500 shares of Class A Common Stock: 182 shares at an exercise price of $18.93, 878 shares at $27.85, and 4,440 shares at $29.33.
• Also on July 10, 2025, Pelish sold a total of 5,500 shares (5,260 shares at a weighted average price of $79.94 and 240 shares at $80.92) as part of a Rule 10b5-1 trading plan adopted on November 1, 2024.
• Following all reported transactions, Pelish's direct beneficial ownership of Class A Common Stock stands at 60,956 shares, representing a net decrease of 2,145 shares from the start of the reported transactions.

Sentiment

Score: 5

Explanation: The filing details routine, pre-planned insider stock transactions (sales for tax obligations and under a 10b5-1 plan, and option exercises), which are standard disclosures and do not inherently indicate positive or negative sentiment regarding the company's performance or outlook.

Positives

• The transactions, including both sales and option exercises, were conducted under pre-arranged Rule 10b5-1 plans, indicating a structured and non-discretionary approach to insider trading.
• Option exercises demonstrate the realization of value from previously granted equity awards, which is a common and expected part of executive compensation.

Negatives

• The net effect of the transactions was a decrease of 2,145 shares in the Chief Scientific Officer's direct beneficial ownership of Class A Common Stock.

Future Outlook

Future vesting of stock options is scheduled, with shares underlying certain options vesting over three or four years in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

Industry Context

This Form 4 filing represents a routine disclosure of insider stock transactions, common across all publicly traded companies. The use of Rule 10b5-1 plans for sales is a standard practice for corporate insiders to manage their equity holdings in compliance with insider trading regulations, providing transparency and mitigating concerns about opportunistic trading.

Stakeholder Impact

• Shareholders: Provides transparency regarding insider stock activity, confirming that transactions were pre-planned and routine, which can help maintain confidence.
• Employees: Highlights the mechanism of equity compensation and its tax implications for executives.

Next Steps

• Continued vesting of remaining stock options for Henry E. Pelish, subject to his continued service to Nuvalent, Inc.

Key Dates

Keywords

Nuvalent, NUVL, Form 4, Insider Trading, Stock Options, Equity Awards, Rule 10b5-1, Chief Scientific Officer, Stock Sale, Stock Acquisition, Beneficial Ownership